Bacil Pharma Intrinsic Value
Bacil Pharma intrinsic value. Bacil Pharma (BACPHAR) median intrinsic value is ₹15.40 from 5 valuation models (range ₹8–₹36), vs current price ₹27.27 — -43.5% downside (Trading Above Calculated Value), margin of safety -77.1%. Read BACPHAR dividend yield for the complete payout history and dividend yield track record.
BACPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Bacil Pharma intrinsic value across 5 models vs current price ₹27.27 — upside/downside and value range per method. Compare with BACPHAR fair value estimate to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹15.40 | ₹12.32 - ₹18.48 | -43.5% | EPS: ₹0.70, Sector P/E: 22x |
| Book Value Method | asset | ₹35.71 | ₹32.14 - ₹39.28 | +30.9% | Book Value/Share: ₹17.86, P/B: 2.0x |
| PEG Ratio Method | growth | ₹8.18 | ₹7.36 - ₹9.00 | -70.0% | EPS Growth: 4.6%, Fair P/E: 3.7x |
| Growth Adjusted P/E | growth | ₹10.81 | ₹9.73 - ₹11.89 | -60.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹16.77 | ₹15.09 - ₹18.45 | -38.5% | EPS: ₹0.70, BVPS: ₹17.86 |
BACPHAR Intrinsic Value vs Market Price — All Valuation Models
Bacil Pharma fair value range ₹8–₹36 vs current market price ₹27.27 across 5 valuation models. For current market price and key ratios, visit Bacil Pharma share price chart.
BACPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Bacil Pharma median intrinsic value ₹15.40, current price ₹27.27 — Trading Above Calculated Value by 43.5%, margin of safety -77.1%.
What is the intrinsic value of BACPHAR?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Bacil Pharma (BACPHAR) is ₹15.40 (median value). With the current market price of ₹27.27, this represents a -43.5% variance from our estimated fair value.
The valuation range spans from ₹8.18 to ₹35.71, indicating ₹8.18 - ₹35.71.
Is BACPHAR undervalued or overvalued?
Based on our multi-method analysis, Bacil Pharma (BACPHAR) appears to be trading above calculated value by approximately 43.5%.
BACPHAR Financial Health — Key Ratios vs Industry Benchmarks
Bacil Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
BACPHAR Cash Flow Quality — Operating & Free Cash Flow
Bacil Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |